



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 11, 2014

Via E-mail

Alicia Grande  
Vice President and Chief Financial Officer  
Catalyst Pharmaceutical Partners, Inc.  
355 Alhambra Circle, Suite 1500  
Coral Gables, FL 33134

**Re: Catalyst Pharmaceutical Partners, Inc.  
Form 10-K for the Fiscal Year Ended December 31, 2013  
Filed March 19, 2014  
File No. 001-033057**

Dear Ms. Grande:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ *Bryan J. Pitko* for

Jeffrey P. Riedler  
Assistant Director

cc: Via E-mail  
Andrew Schwartz, Esq.  
Akerman LLP